Breaking News Instant updates and real-time market news.

ATRS

Antares Pharma

$2.60

-0.04 (-1.52%)

, PFE

Pfizer

$40.53

0.87 (2.19%)

07:08
08/06/18
08/06
07:08
08/06/18
07:08

Antares Pharma enters into development with Pfizer

Antares Pharma (ATRS) announced that it has entered into an agreement with Pfizer (PFE) to develop a combination drug device rescue pen. This rescue pen will utilize the Antares QuickShot auto injector and an undisclosed Pfizer drug. Pfizer will pay for the development of the product and will be responsible for obtaining FDA approval of the combination product. The parties intend to enter into a separate supply agreement pursuant to which Antares will provide fully packaged commercial ready finished product to Pfizer at cost plus margin and Pfizer will then be responsible for commercializing the product in the United States, pending FDA approval. Antares will then receive royalties on net sales on the combination product.

ATRS

Antares Pharma

$2.60

-0.04 (-1.52%)

PFE

Pfizer

$40.53

0.87 (2.19%)

  • 07

    Aug

  • 22

    Aug

  • 10

    Sep

ATRS Antares Pharma
$2.60

-0.04 (-1.52%)

05/08/18
HCWC
05/08/18
NO CHANGE
Target $4
HCWC
Buy
Antares target raised to $4 on higher Xyosted confidence at H.C. Wainwright
H.C. Wainwright analyst Oren Livnat said that Antares Pharma reported "solid" Q1 results but "most importantly...finally explicitly confirmed a key aspect of the Xyosted filing," specifically that the company already conducted an ambulatory blood pressure monitoring study as part of the supplemental safety study ahead of the NDA submission. That fact, along with Antares' ability to re-submit the NDA just a week after receiving the minutes from the FDA Type-A meeting, increases his confidence in Xyosted approval coming in 2018, Livnat said. He raised his view of Xyosted's probability of success to 70% from 40% and increased his price target to $4 from $3.50 on Antares shares. Livnat keeps a Buy rating on the stock.
10/23/17
JANY
10/23/17
NO CHANGE
JANY
Neutral
Antares CRL doesn't raise issues for Amag Pharmaceuticals, says Janney Capital
Janney Capital analyst Ken Trbovich noted that the FDA complete response letter issued to Antares (ATRS) for Xyosted did not pertain to the Quickshot subcutaneous autoinjector, which raises his confidence the FDA will not identify such issues as a short coming of the sNDA for Amag Pharmaceuticals' (AMAG) Makena SQ. However, he keeps a Neutral rating on Amag shares, noting that the primary uncertainty for the sNDA for Makena SQ is the fact that its peak plasma levels is higher than the upper bound the FDA uses to define bioequivalence.
10/23/17
RAJA
10/23/17
NO CHANGE
Target $3.4
RAJA
Strong Buy
Antares Pharma maintained as a Strong Buy at Raymond James
Raymond James analyst Elliot Wilbur said the FDA's CRL on Antares Pharma (ATRS) XYOSTED was an unexpected and significant setback, but weakness in shares since the October disclosure effectively prices XYOSTED at zero, and substantially undervalues other development programs, especially ANDA products with Teva (TEVA). Wilbur is not writing-off XYSTED yet and is pushing out an expected launch to 2H19 from early 2018 previously, and is now discounting the probability of success at 50% versus 100% prior to the CRL. The analyst maintains asset values for Antares' non-XYOSTED assets are worth $2.50 per share using a sum-of-the-parts valuation and adjusted his price target to $3.40 from $4.20 on shares. Wilbur maintains a Strong Buy rating on Antares
10/23/17
MSCO
10/23/17
NO CHANGE
Target $26
MSCO
Overweight
Antares CRL should have limited read through to Amag, says Morgan Stanley
After Antares Pharma (ATRS) announced that it has received a FDA complete response letter about the new drug application for Xyosted due to two deficiencies related to clinical data, Morgan Stanley analyst Thomas Smith said the CRL should have limited read through to Amag Pharmaceuticals (AMAG), which has partnered with Antares for technology being used in subcutaneous Makena. The CRL is not related to the device or manufacturing, noted Smith, who adds that investor relief over the minimal Makena read through could lead to a rally in Amag shares following the recent weakness. He keeps 60% probability of success for Makena SC and maintains an Overweight rating on Amag shares.
PFE Pfizer
$40.53

0.87 (2.19%)

07/18/18
WELS
07/18/18
NO CHANGE
WELS
Novartis report has negative read through for Teva, Mylan, says Wells Fargo
Wells Fargo analyst David Maris noted that Novartis (NVS) lowered its 2018 guidance for Sandoz along with its Q2 report and reportedly told Bloomberg that it would consider selling the generic drug unit. He sees a negative read through for companies with large U.S. commodity generic exposure, such as Teva (TEVA) and Mylan (MYL), from Novartis' report, Maris tells investors. He also noted that Novartis said it will not increase prices on its drugs in the U.S. for the rest of 2018, as Pfizer (PFE) recently has also said, calling this "a wise approach and correct read of the increasing intensity of the scrutiny around rising healthcare costs." Maris continues to expect the " chilling effect" on price increases to spread through the industry. Lastly, the analyst pointed out that the Amgen-partnered (AMGN) launch of Aimovig is off to a strong start, which he believes bodes well for Teva's fremanezumab and Eli Lilly's (LLY) galcanezumab.
07/18/18
PIPR
07/18/18
NO CHANGE
Target $450
PIPR
Overweight
Piper maintains Overweight on Regeneron on tanezumab news
Piper Jaffray analyst Christopher Raymond keeps an Overweight rating on Regeneron Pharmaceuticals (REGN) on news that tanezumab, Pfizer (PFE) and Eli Lilly's (LLY) anti-NGF antibody that is a competitor to Regeneron's fasinumab, successfully completed the first of several Phase 3 trials. Fasinumab remains an unmodeled opportunity, but the read-through from tanezumab is positive and the market for an effective, non-opioid chronic pain treatment is "massive," Raymond tells investors in a research note. The analyst points out that Regeneron and Teva (TEVA) still expect to report Phase 3 data starting later this year. Raymond keeps an Overweight rating on Regeneron with a $450 price target.
07/17/18
CANT
07/17/18
NO CHANGE
CANT
Overweight
Aclaris offers best risk/reward of hair loss players, says Cantor Fitzgerald
The potential for JAK inhibitors to treat alopecia areata may be underappreciated by investors because the Street does not appear to be ascribing enough value to the opportunity, Cantor Fitzgerald analyst Louise Chen tells investors in a research note. Of the three companies she covers developing JAKs for hair loss, Aclaris Therapeutics (ACRS), Eli Lilly (LLY) and Pfizer (PFE), the analyst believes Aclaris offers the best risk/reward and greatest upside potential. The company has a market cap below $700M and two potential "shots on goal" for alopecia areata, Chen writes. She estimates combined peak sales of $1B-plus for both opportunities and keeps an Overweight rating on Aclaris. The physicians the analyst spoke to believe the company's JAKs for hair loss will work.
07/17/18
HCWC
07/17/18
NO CHANGE
Target $42
HCWC
Buy
uniQure pullback on Pfizer study unwarranted, says H.C. Wainwright
H.C. Wainwright analyst Debjit Chattopadhyay notes that shares of uniQure (QURE) dropped 11% yesterday after Pfizer (PFE) initiated an "open-label, non-investigational product, multi-center, lead-in study to evaluate at least 6 months of prospective efficacy and selected safety data of factor IX prophylaxis replacement therapy in moderate to severe adult Hemophilia B subjects who are negative for neutralizing antibodies to adeno-associated virus vector-spark100". This has been potentially misconstrued as the initiation of the Phase 3 study, suggesting competitive threats for uniQure earlier than anticipated, Chattopadhyay tells investors in a research note. However, this is not to be mistaken as a gene therapy Phase 3 program, as there is no gene therapy treatment cohort, the analyst adds. Further, Chattopadhyay points out that Pfizer's observation study is expected to be completed during November of 2020, which he believes puts uniQure at least a year, if not more, ahead. In addition, the analyst continues to believe that Pfizer is likely to encounter intellectual property headwinds given uniQure's patent asset protecting both the mPadua gene cassette and its method of use to treat hemoglobinopathies. He views the selloff yesterday in shares of uniQure as unwarranted and keeps a Buy rating on the name with a $42 price target.

TODAY'S FREE FLY STORIES

MTN

Vail Resorts

$217.80

0.5 (0.23%)

, TOCA

Tocagen

$9.55

0.42 (4.60%)

10:21
04/26/19
04/26
10:21
04/26/19
10:21
Initiation
Fly Intel: Top five analyst initiations »

Catch up on today's…

MTN

Vail Resorts

$217.80

0.5 (0.23%)

TOCA

Tocagen

$9.55

0.42 (4.60%)

DOW

Dow Inc.

$55.28

-0.05 (-0.09%)

GILD

Gilead

$64.80

0.68 (1.06%)

REED

Reed's

$3.94

0.06 (1.55%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Apr

  • 02

    May

  • 02

    May

  • 03

    May

  • 06

    May

  • 08

    May

  • 18

    May

  • 29

    May

SBUX

Starbucks

$75.44

-1.63 (-2.12%)

, AXTA

Axalta Coating

$26.65

-0.06 (-0.22%)

10:21
04/26/19
04/26
10:21
04/26/19
10:21
Downgrade
Fly Intel: Top five analyst downgrades »

Catch up on today's…

SBUX

Starbucks

$75.44

-1.63 (-2.12%)

AXTA

Axalta Coating

$26.65

-0.06 (-0.22%)

RACE

Ferrari

$134.74

-0.83 (-0.61%)

STX

Seagate

$44.77

-1.32 (-2.86%)

WDC

Western Digital

$49.77

-3.18 (-6.01%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Apr

  • 30

    Apr

  • 01

    May

  • 07

    May

  • 06

    Jun

CLF

Cleveland-Cliffs

$9.83

0.12 (1.24%)

, ARGO

Argo Group

$75.29

1.08 (1.46%)

10:21
04/26/19
04/26
10:21
04/26/19
10:21
Upgrade
Fly Intel: Top five analyst upgrades »

Catch up on today's…

CLF

Cleveland-Cliffs

$9.83

0.12 (1.24%)

ARGO

Argo Group

$75.29

1.08 (1.46%)

ITW

Illinois Tool Works

$152.18

0.915 (0.60%)

MDCO

The Medicines Co.

$31.48

1.64 (5.50%)

ESPR

Esperion

$44.11

1.09 (2.53%)

SFLY

Shutterfly

$43.11

0.81 (1.91%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Apr

  • 03

    May

  • 06

    May

  • 07

    May

  • 08

    May

  • 15

    May

  • 11

    Jun

MDLZ

Mondelez

$49.97

-0.02 (-0.04%)

10:20
04/26/19
04/26
10:20
04/26/19
10:20
Options
Mondelez puts active ahead of earnings »

Mondelez puts active…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Apr

  • 30

    Apr

  • 15

    May

  • 29

    May

10:20
04/26/19
04/26
10:20
04/26/19
10:20
General news
The upwardly-revised April Michigan sentiment drop »

The upwardly-revised…

10:20
04/26/19
04/26
10:20
04/26/19
10:20
General news
Treasury Action: yields have extended slightly lower »

Treasury Action: yields…

WBC

Wabco

$133.12

-0.08 (-0.06%)

10:17
04/26/19
04/26
10:17
04/26/19
10:17
Downgrade
Wabco rating change  »

Wabco downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

10:17
04/26/19
04/26
10:17
04/26/19
10:17
Technical Analysis
NASDAQ market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DIS

Disney

$139.40

2.1 (1.53%)

, SSNLF

Samsung

$0.00

(0.00%)

10:16
04/26/19
04/26
10:16
04/26/19
10:16
Earnings
Fly Intel: What to watch in Spotify earnings report »

Spotify (SPOT) is…

DIS

Disney

$139.40

2.1 (1.53%)

SSNLF

Samsung

$0.00

(0.00%)

SPOT

Spotify

$134.88

2.08 (1.57%)

FOX

Fox Corp.

$37.49

-0.13 (-0.35%)

CMCSA

Comcast

$43.19

0.24 (0.56%)

T

AT&T

$30.64

0.305 (1.01%)

AMZN

Amazon.com

$1,905.19

2.66 (0.14%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Apr

  • 28

    Apr

  • 29

    Apr

  • 06

    May

  • 07

    May

  • 08

    May

  • 09

    May

  • 10

    May

  • 18

    May

  • 20

    May

  • 22

    May

  • 03

    Jun

  • 24

    Jul

$NYE

NYSE Market Internals

$0.00

(0.00%)

10:16
04/26/19
04/26
10:16
04/26/19
10:16
Technical Analysis
NYSE market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AMZN

Amazon.com

$1,901.49

-1.04 (-0.05%)

, UPS

UPS

$103.84

-1.29 (-1.23%)

10:11
04/26/19
04/26
10:11
04/26/19
10:11
On The Fly
Amazon 'goes for the jugular' with one-day Prime shipping »

Shares of Amazon.com…

AMZN

Amazon.com

$1,901.49

-1.04 (-0.05%)

UPS

UPS

$103.84

-1.29 (-1.23%)

WMT

Walmart

$101.87

-1.65 (-1.59%)

TGT

Target

$78.14

-3.6 (-4.40%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    May

  • 09

    May

  • 10

    May

  • 16

    May

  • 21

    May

  • 22

    May

  • 29

    May

  • 03

    Jun

  • 05

    Jun

  • 05

    Jun

  • 07

    Jun

  • 24

    Jul

  • 13

    Nov

USO

United States Oil Fund

$13.29

-0.23 (-1.70%)

10:10
04/26/19
04/26
10:10
04/26/19
10:10
Options
Size option block in US Oil Fund as shares slip »

Size option block in US…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RIG

Transocean

$8.74

-0.19 (-2.13%)

10:05
04/26/19
04/26
10:05
04/26/19
10:05
Options
Transocean call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Apr

  • 22

    May

10:05
04/26/19
04/26
10:05
04/26/19
10:05
General news
U.S. consumer sentiment improved to 97.2 in the final April reading »

U.S. consumer sentiment…

SPX

S&P 500

$0.00

(0.00%)

, SPY

SPDR S&P 500 ETF Trust

$291.70

-0.42 (-0.14%)

10:04
04/26/19
04/26
10:04
04/26/19
10:04
General news
Trump says trade deal with China 'going very well' »

When speaking to…

SPX

S&P 500

$0.00

(0.00%)

SPY

SPDR S&P 500 ETF Trust

$291.70

-0.42 (-0.14%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

10:02
04/26/19
04/26
10:02
04/26/19
10:02
General news
Consumer Sentiment Index data reported »

Consumer Sentiment Index…

FII

Federated Investors

$30.30

-3.27 (-9.74%)

10:00
04/26/19
04/26
10:00
04/26/19
10:00
Hot Stocks
Federated Investors falls -9.4% »

Federated Investors is…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Apr

ATEN

A10 Networks

$6.42

-0.86 (-11.81%)

10:00
04/26/19
04/26
10:00
04/26/19
10:00
Hot Stocks
A10 Networks falls -11.5% »

A10 Networks is down…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BGG

Briggs & Stratton

$10.82

-2.785 (-20.47%)

10:00
04/26/19
04/26
10:00
04/26/19
10:00
Hot Stocks
Briggs & Stratton falls -20.5% »

Briggs & Stratton is…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Apr

  • 15

    Aug

ENVA

Enova International

$29.65

3.12 (11.76%)

10:00
04/26/19
04/26
10:00
04/26/19
10:00
Hot Stocks
Enova International rises 11.1% »

Enova International is up…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    May

  • 09

    May

  • 30

    May

  • 13

    Nov

PRO

Pros Holdings

$51.24

6.185 (13.73%)

10:00
04/26/19
04/26
10:00
04/26/19
10:00
Hot Stocks
Pros Holdings rises 14.1% »

Pros Holdings…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    May

SAH

Sonic Automotive

$19.80

1.97 (11.05%)

10:00
04/26/19
04/26
10:00
04/26/19
10:00
Hot Stocks
Sonic Automotive rises 11.6% »

Sonic Automotive is up…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Nov

WMT

Walmart

$101.02

-2.5 (-2.42%)

, TGT

Target

$77.57

-4.17 (-5.10%)

09:57
04/26/19
04/26
09:57
04/26/19
09:57
Hot Stocks
Walmart, Target slip as Amazon invests in one-day shipping for Prime members »

Shares of Walmart (WMT)…

WMT

Walmart

$101.02

-2.5 (-2.42%)

TGT

Target

$77.57

-4.17 (-5.10%)

AMZN

Amazon.com

$1,913.34

10.81 (0.57%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    May

  • 10

    May

  • 16

    May

  • 21

    May

  • 22

    May

  • 29

    May

  • 03

    Jun

  • 05

    Jun

  • 07

    Jun

  • 13

    Nov

MAT

Mattel

$13.25

0.95 (7.72%)

, F

Ford

$10.17

0.76 (8.08%)

09:55
04/26/19
04/26
09:55
04/26/19
09:55
Options
Early notable gainers among liquid option names on April 26th »

Notable gainers among…

MAT

Mattel

$13.25

0.95 (7.72%)

F

Ford

$10.17

0.76 (8.08%)

VRSN

VeriSign

$198.28

9.04 (4.78%)

EQT

EQT Corporation

$20.85

0.685 (3.40%)

COF

Capital One

$91.94

3.85 (4.37%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    May

  • 02

    May

  • 03

    May

  • 09

    May

  • 16

    May

  • 23

    May

  • 11

    Jun

  • 12

    Jun

  • 24

    Jul

  • 23

    Oct

09:50
04/26/19
04/26
09:50
04/26/19
09:50
General news
U. Michigan sentiment preview: »

U. Michigan sentiment…

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.